Aurora Cannabis (TSE:ACB) Given New C$5.00 Price Target at Canaccord Genuity Group

Aurora Cannabis (TSE:ACB) had its target price cut by equities research analysts at Canaccord Genuity Group from C$6.50 to C$5.00 in a research report issued on Tuesday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 26.26% from the stock’s current price.

Separately, TD cut their price target on Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating on the stock in a research note on Friday, June 12th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of C$7.17.

Aurora Cannabis Stock Down 3.9%

TSE:ACB traded down C$0.16 during trading hours on Tuesday, hitting C$3.96. The stock had a trading volume of 326,585 shares, compared to its average volume of 410,117. The company has a market cap of C$245.29 million, a PE ratio of -1.85 and a beta of 0.17. The business has a 50 day simple moving average of C$4.60 and a two-hundred day simple moving average of C$5.12. Aurora Cannabis has a 1-year low of C$3.77 and a 1-year high of C$9.33. The company has a current ratio of 5.94, a quick ratio of 2.48 and a debt-to-equity ratio of 4.66.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings results on Thursday, June 11th. The company reported C($0.99) earnings per share (EPS) for the quarter. The firm had revenue of C$38.01 million for the quarter. Aurora Cannabis had a negative return on equity of 7.25% and a negative net margin of 12.13%. Analysts predict that Aurora Cannabis will post -0.22 EPS for the current year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.